HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Immunocore Holdings (NASDAQ:IMCR) and maintained a price target of $100.
May 30, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Immunocore Holdings and maintained a price target of $100.
The reiteration of a Buy rating and the maintenance of a $100 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100